Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 89 results for "yeda research development company"

US patent office rules in favour of Mylan: Natco Pharma

Natco Pharma moves up on the bourses

SENSEX 28467.24 43.76 0.15% NIFTY 8781.35 6.70 0.08% Industry: Medical/Healthcare Company Natco Pharma Ltd Natco Pharma is currently trading at Rs. 677.80, up by 0.90 points or 0.13% from its previous closing of Rs. 676.90 on ..., 1 month ago

324 images for yeda research development company

Minyanville, 2 days ago
Yahoo! Singapore, 2 days ago
Clean Technica, 21 hours ago
Clean Technica, 21 hours ago, 1 week ago
Broadway World, 2 days ago
Tech2, 1 day ago
Aviation International News, 1 week ago
Pharmaceutical Business Review, 53 minutes ago
CHINAdaily Europe, 4 hours ago

Mylan wins round in fight with Teva over multiple sclerosis drug

WASHINGTON, Aug 24 (Reuters) - Pharmaceutical company Mylan NV has won a round in its fight with Teva Pharmaceutical Industries Ltd at the U.S. Patent and Trademark Office, which said on Wednesday that two patents for the multiple sclerosis drug ...
 Yahoo! Finance2 months ago UPDATE 2-Mylan wins round in fight with Teva over multiple sclerosis drug  Reuters UK2 months ago UPDATE 1-Mylan wins round in fight with Teva over multiple sclerosis drug  Reuters UK2 months ago

Will The Crashing Copaxone Franchise Spell Doom For Teva Pharmaceutical?

Why is Copaxone franchise so important for Teva Pharmaceutical? Teva Pharmaceutical (NASDAQ: TEVA ) offers two formulations of Copaxone for multiple sclerosis patients, one with dosage strength of 20mg/ml and the other which is long-acting ...
 Seeking Alpha3 weeks ago Shares of Teva Pharmaceuticals fall after US Patent Office invalidates two patents  CNBC2 months ago
Share Market Updates

HC Stocks in Hub! Exelixis, Inc. (EXEL), Mylan NV (NASDAQ:MYL)

Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Friday session in green amid volatile trading. The shares closed up +0.15 points or 1.02 % at $ 14.89 with 5.49 million shares getting traded. Post opening the session at $ 14.74 , the shares hit an ...
 Share Market Updates1 month ago HC Stocks in Top Row! Mylan NV (MYL), Zoetis Inc (NYSE:ZTS)  Share Market Updates1 month ago HC Stocks Overview= Mylan NV (NASDAQ:MYL), St. Jude Medical, Inc. (STJ)  Share Market Updates1 month ago HC Stocks Indications= Mylan NV (MYL), Medtronic PLC (NYSE:MDT)  Share Market Updates1 month ago

Appointments, Resignations, Deaths (9/30/2016)

Central Piedmont Community College, Kandi Deitemeyer City University of Seattle, Randy Frisch Coastal Carolina Community College, David Heatherly Cooper Union for the Advancement of Science and Art, Laura Sparks Ivy Tech Community College ...
 Chronicle of Higher Education1 month ago

RBC Capital Markets Lowers Mylan Inc. (MYL) Price Target to $48.00

The stock has received "OVERWEIGHT" rating after consensus analysis from analysts. 13 number of analysts have estimated the sales of the company for the quarter ending Oct 28, 2016- Nov 1, 2016, analysts estimated mean sale target of 3289.14 ...
 Equilibrio Informativo1 month ago

AKORN : Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn

/PRNewswire/ -- Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, presents four stocks within the Generic Drugs space for review, one of which ...
 4 Traders1 month ago Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn  Asian Hospital & Healthcare Management1 month ago
Bidness Etc

UPDATE 2-Third U.S. patent on Tevas MS drug Copaxone invalidated

(Adds comment from Teva, background) By Andrew Chung NEW YORK, Sept 1 Teva Pharmaceutical Industries on Thursday lost a third patent for its top-selling multiple sclerosis treatment as U.S. patent officials ruled that Copaxone did not ...
 Reuters UK1 month ago Teva Pharmaceutical Industries Ltd: PTAB Invalidates Two Patents; Copaxone Generics Unlikely in '17  Bidness Etc2 months ago Teva Plunges After Two U.S. Copaxone Patents Invalidated (3)  La Repubblica2 months ago
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less